Loss of expression of LyGDI (ARHGDIB), a rho GDP-dissociation inhibitor, in Hodgkin lymphoma.

Loss of expression of LyGDI (ARHGDIB), a rho GDP-dissociation inhibitor, in Hodgkin lymphoma. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Loss of expression of LyGDI (ARHGDIB), a rho GDP-dissociation inhibitor, in Hodgkin lymphoma. Abstract Text:

Liya Ma,Gaixiang Xu,Anna Sotnikova,Monika Szczepanowski,Maciej Giefing,Kristina Krause,Matthias Krams,Reiner Siebert,Jie Jin,Wolfram Klapper,Liya Ma,Gaixiang Xu,Anna Sotnikova,Monika Szczepanowski,Maciej Giefing,Kristina Krause,Matthias Krams,Reiner Siebert,Jie Jin,Wolfram Klapper,

The guanosine triphosphatase (GTPase) inhibitor LyGDI (ARHGDIB, Ly/D4-GDI, RhoGDIb or RhoGDI 2) is abundantly expressed in haematopoetic cells and possibly plays a role in the onset of apoptosis. Gene expression profiling of Hodgkin cell lines revealed that LyGDI expression was downregulated in these cell lines. The present study evaluated the expression of LyGDI in Hodgkin cells in vivo and studied the function of LyGDI in Hodgkin cell lines in vitro. Our results showed that virtually all Hodgkin and Reed-Sternberg cells in classical Hodgkin lymphoma lacked LyGDI protein expression. On the other hand, almost all non-Hodgkin lymphomas, except for anaplastic large cell lymphomas, expressed LyGDI protein. Transfection of the classical Hodgkin cell line L428 with a vector containing full-length LyGDI-induced apoptosis in a subset of cells. However, the majority of Hodgkin cells with transgenic expression of LyGDI escaped apoptosis. Our data show that lack of LyGDI expression is a frequent feature of cHL but that it is not of vital importance for the growth and survival of these cells.

Loss of expression of LyGDI (ARHGDIB), a rho GDP-dissociation inhibitor, in Hodgkin lymphoma. Publishing Authors By Initials

L Ma,G Xu,A Sotnikova,M Szczepanowski,M Giefing,K Krause,M Krams,R Siebert,J Jin,W Klapper,L Ma,G Xu,A Sotnikova,M Szczepanowski,M Giefing,K Krause,M Krams,R Siebert,J Jin,W Klapper,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Loss of expression of LyGDI (ARHGDIB), a rho GDP-dissociation inhibitor, in Hodgkin lymphoma. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: British journal of haematology

VOLUME: 139

Page Numbers: 217-23

Journal Abbreviation: Br. J. Haematol.

ISSN: 0007-1048

DAY: 27

MONTH: Oct

YEAR: 2007

Loss of expression of LyGDI (ARHGDIB), a rho GDP-dissociation inhibitor, in Hodgkin lymphoma. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 372544

Loss of expression of LyGDI (ARHGDIB), a rho GDP-dissociation inhibitor, in Hodgkin lymphoma. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Loss of expression of LyGDI (ARHGDIB), a rho GDP-dissociation inhibitor, in Hodgkin lymphoma. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Loss of expression of LyGDI (ARHGDIB), a rho GDP-dissociation inhibitor, in Hodgkin lymphoma.

AFFILIATION: Department of Pathology, Schleswig-Holstein University Hospitals, Kiel, Germany.

Country: England

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Br J Haematol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Loss of expression of LyGDI ARHGDIB, a rho GDP-dissociation inhibitor, in Hodgkin lymphoma Related Publications

• A multidimensional multispecies continuum model for heterogeneous biofilm development.
• Age-related pattern of KI and WU polyomavirus infection.
• Analysis of the transcriptional regulation of the FABP2 promoter haplotypes by PPARgamma/RXRalpha and Oct-1.
• Cardiac rehabilitation in a sheltered workshop.
• Description of mechanical response including detachment using a novel particle model of biofilm/flow interaction.
• Divalproex sodium in migraine prophylaxis: a dose-controlled study.
• First clinical application of a navigation-controlled shaver in paranasal sinus surgery.
• HSV-1 and HSV-2 in herpes simplex encephalitis: a study of sixty-four cases in the United Kingdom.
• Loss of expression of LyGDI (ARHGDIB), a rho GDP-dissociation inhibitor, in Hodgkin lymphoma.
• OC142: Labor and delivery ultrasound service after office hours: How does it work?